Delivery Order SPE2DB20D3103-SPE2DB25FP0P9
Award Date
6/5/25
Potential Completion Date
6/6/25
Potential Value
$2.5K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,666.41, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,388.96 firm fixed-price Delivery Order covers the supply of HEMABATE 250 MCG/ML ampules, with a period of performance through June 11, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,030.16 firm fixed-price delivery order is for the supply of HEMABATE 250 MCG/ML AMPULML, a medication used in various medical treatments. The contract has an ultimate completion date of December 18, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract is a firm-fixed-price delivery order with a ceiling value of $2,054.69 and a period of performance ending on May 29, 2025. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not set aside for any specific business type....
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $1,656.93 and a performance period through May 28, 2025. The contract is not set-aside and was awarded on May 27, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award is for the pharmaceutical product HEMABATE 250MCG/ML 10S, awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,718.21, is a Delivery Order issued by the Defense Logistics Agency (DLA) Troop Support Medical, a division of the Department of Defense. It has an ultimate completion date of November 12, 2024. The contract is a Firm Fixed Price agreement, with no set-aside designation,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEMABATE 250 MCG/ML AMPULML. The award, valued at $6,555.04, is a firm fixed-price Delivery Order with a completion date of February 16, 2024. This contract does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen holds a significant Indefinite Delivery...
The Defense Logistics Agency (DLA) awarded a $5,321.60 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp to provide HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. This award was issued under the DLA Troop Support Medical Indefinite Delivery Contract, which has a potential value of up to $999,999,999 for delivery of a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside...
This federal contract award was made by the Medical Supply Chain, a component of the Defense Logistics Agency (DLA), to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,393.64 firm fixed-price delivery order is for 250 MCG/ML Hemabate ampules, a medication used to control postpartum bleeding. The contract has an ultimate completion date of August 20, 2024 and does not utilize any set-aside designation. As one of the largest pharmaceutical distributors in the U.S.,...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The contract, valued at $4,862.12, is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. This is a Firm Fixed Price delivery order contract with an ultimate completion date of October 8, 2024. The contract was awarded on October 7, 2024 and does not have a set-aside designation. AmerisourceBergen, a major...